[go: up one dir, main page]

WO2009117278A3 - Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers - Google Patents

Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers Download PDF

Info

Publication number
WO2009117278A3
WO2009117278A3 PCT/US2009/036616 US2009036616W WO2009117278A3 WO 2009117278 A3 WO2009117278 A3 WO 2009117278A3 US 2009036616 W US2009036616 W US 2009036616W WO 2009117278 A3 WO2009117278 A3 WO 2009117278A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolopyridinyl
amino
substituted biaryl
processes
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/036616
Other languages
French (fr)
Other versions
WO2009117278A2 (en
Inventor
Jeffrey T. Kuethe
Yong Li Zhong
Nobuyoshi Yasuda
Thomas J. Tucker
Philip Pye
Yangfeng Zhang
Robert Tynebor
David C. Dubost
Gregory L. Beutner
David M. Tellers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2009117278A2 publication Critical patent/WO2009117278A2/en
Publication of WO2009117278A3 publication Critical patent/WO2009117278A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Processes for preparing certain (amino-pyrazolopyridinyl)methoxy-substituted biaryl ethers and their salts are described. The substituted biaryl ethers are useful as HIV non-nucleoside reverse transcriptase inhibitors. The processes include coupling a biaryl ether with a suitably protected and activated pyrazolopyridinyl methanol and then removing the protective groups from the coupled product to provide the desired substituted biaryl ether in the form of a sulfonate salt or a sulfate salt. Earlier reaction steps and the intermediates employed and obtained therein are also described. Crystalline HCl and sulfate salts of a particular (amino-pyrazolopyridmyl)-methoxy~substituted biaryl ether are described as well.
PCT/US2009/036616 2008-03-20 2009-03-10 Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers Ceased WO2009117278A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7008408P 2008-03-20 2008-03-20
US61/070,084 2008-03-20
US19526208P 2008-10-06 2008-10-06
US61/195,262 2008-10-06

Publications (2)

Publication Number Publication Date
WO2009117278A2 WO2009117278A2 (en) 2009-09-24
WO2009117278A3 true WO2009117278A3 (en) 2009-11-12

Family

ID=40602516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036616 Ceased WO2009117278A2 (en) 2008-03-20 2009-03-10 Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers

Country Status (1)

Country Link
WO (1) WO2009117278A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021442A1 (en) * 2005-07-22 2007-01-25 Saggar Sandeep A HIV reverse transcriptase inhibitors
WO2008076223A1 (en) * 2006-12-13 2008-06-26 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021442A1 (en) * 2005-07-22 2007-01-25 Saggar Sandeep A HIV reverse transcriptase inhibitors
WO2008076223A1 (en) * 2006-12-13 2008-06-26 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEUTNER, GREGORY L. ET AL: "Expedient Synthesis of 3-Alkoxymethyl- and 3-Aminomethyl-Pyrazolo[3,4-b]pyridines", JOURNAL OF ORGANIC CHEMISTRY, vol. 74, no. 2, 12 September 2008 (2008-09-12), pages 789 - 794, XP002527871, ISSN: 0022-3263 *
KUETHE, JEFFREY T. ET AL: "Development of a Sequential Tetrahydropyran and Tertiary Butyl Deprotection: High-Throughput Experimentation, Mechanistic Analysis, and DOE Optimization", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 13, no. 3, 2 March 2009 (2009-03-02), XP002527872, ISSN: 1083-6160, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/op8002739> [retrieved on 20090513] *
TUCKER, THOMAS J. ET AL: "Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2- chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 20, 1 October 2008 (2008-10-01), pages 6503 - 6511, XP002527873, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2009117278A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
NZ599306A (en) Process for the preparation of compounds useful as inhibitors of sglt2
CR7691A (en) NEW IVABRADINE SYNTHESIS PROCEDURE AND ITS ADDITION SALTS TO A PHARMACEUTICALLY ACCEPTABLE ACID
WO2010111436A3 (en) Antiviral compounds and uses thereof
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
WO2009083940A3 (en) Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts
PH12014500713A1 (en) Methods for producing 4,4-difluoro-3,4-dihydroisoquinoline derivatives
MY152281A (en) 4-pyrimidinesulfamide derivative
WO2010140765A3 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
MX2013000773A (en) Process for preparing aminobenzoylbenzofuran derivatives.
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
MX2013000295A (en) Process of preparing a thrombin specific inhibitor.
WO2010126168A3 (en) Solid preparation
WO2012103071A3 (en) Compounds and compositions
WO2009047499A3 (en) Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
UA111868C2 (en) METHOD OF PREPARING ETHERS (5-FLUOR-2-METHYL-3-QUINOLIN-2-ILMETHYLINDOL-1-IL) -ACETIC ACID
WO2012038979A3 (en) A process for preparation of ertapenem
MX2013000294A (en) Intermediates and process for preparing a thrombin specific inhibitor.
WO2009117278A3 (en) Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers
WO2012164242A8 (en) Process for the preparation of paliperidone
WO2012106584A3 (en) Pitavastatin salts
NZ598278A (en) Process for preparing biphenyl imidazole compounds
WO2012012339A3 (en) Glycosylated acetaminophen pro-drug analogs
PH12013501876A1 (en) Hydrocarbon fuel production method
WO2011048612A3 (en) Process for preparation of propargylated aminoindans or pharmaceutically acceptable salts thereof
WO2011079935A3 (en) A process for the preparation and isolation of vardenafil and salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722747

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09722747

Country of ref document: EP

Kind code of ref document: A2